Stock Ratings / Health Care / SNDX / options

OPK (39) LBRX (43) SLN (34) NKTR (33) ⌘ Pro Terminal →

Syndax Pharmaceuticals Inc. (SNDX) Options Positioning, Max Pain & Unusual Sweeps

$14.15 -1.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $14.09

Syndax Pharmaceuticals Inc. (SNDX) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.26B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $14.09 (-0.40%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-12.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNDX)Realized 20D OHLCV Swing Band: ±10.4%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY SNDX SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+13/20 pts (42% of score)

FRED Regime × Technicals: 11% of 52W Range • RSI-14 at 35.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)

20D Institutional Volume Accumulation (±10.4% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$16.99-24.1% Next Q

Q2 (-2Q)

Grade E$12.90+3.9% Next Q

Q3 (-1Q)

Grade E$13.40+5.6% Next Q

Current

Grade E$14.15-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SNDX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SNDX currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($17.18) and Max Pain ($14.86) forces dealer call-delta covering toward $26.87.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SNDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±10.4%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (SNDX)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for SNDX.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNDX)

✓Walkthrough of SNDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SNDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.97%▼ DESCENDING CHANNEL

2026-10-30O $14.06H $14.35L $13.61C $14.15VOL 2.54M

RES: $17.06SUP: $12.04SMA50: $17.18SMA200: $20.23

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SNDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SNDX Butterfly Map → + Track SNDX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SNDX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SNDX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SNDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNDX)

Health Care Rank #910 of 1016 ⚔️ OPK vs SNDX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SNDX vs. OPK, LBRX, SLN, NKTR)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Syndax Pharmaceuticals Inc. (SNDX) ranks #910 by composite RQD confidence (31/100, grade E) and #330 by equity capitalization ($1.26B). Within this direct 5-issuer industry benchmark cohort, SNDX leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. LBRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with SNDX at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SNDX ACTIVE Syndax Pharmaceuticals Inc.	E	31/100	—	—	-35.0%	-1.19%	$1.26B	Benchmark Subject
OPK OPKO Health Inc.	D-	39/100	—	33.9%	-10.2%	+2.47%	$1.24B	/opk-vs-sndx →
LBRX LB Pharmaceuticals Inc	D-	43/100	—	—	-8.4%	+0.80%	$1.30B	/lbrx-vs-sndx →
SLN Silence Therapeutics Plc American Depository Share	E	34/100	—	61.5%	-35.0%	+0.46%	$1.23B	/sln-vs-sndx →
NKTR Nektar Therapeutics	E	33/100	—	96.0%	-35.0%	+1.63%	$1.34B	/nktr-vs-sndx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001395937

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Syndax Pharmaceuticals Inc. (SNDX) reported GAAP revenue of $172.4M (+627.8% vs. FY2024 revenue of $23.7M ) , GAAP net income of -$285.4M, operating cash flow of -$323.0M, and free cash flow of -$323.2M (-17.6% YoY). On the balance sheet, SNDX closed FY2025 with $529.7M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$172.4M	-$285.4M	-$323.0M	-$323.2M	$529.7M	—
FY2024 (FY)	2024-12-31	$23.7M	-$318.8M	-$274.9M	-$274.9M	$724.8M	—
FY2023 (FY)	2023-12-31	$0	-$209.4M	-$160.6M	-$160.6M	—	—

3. SNDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SNDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $14.15 (-1.19% 1D, market cap $1.26B). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SNDX ranks #910 in composite RQD confidence.

How does SNDX compare to OPK and LBRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SNDX carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OPK (OPKO Health Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -10.2%, cap $1.24B) and LBRX (LB Pharmaceuticals Inc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -8.4%, cap $1.30B). Among the 5-stock peer group, SNDX leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SNDX?

Per SNDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001395937), Syndax Pharmaceuticals Inc. generated $172.4M in revenue (+627.8% YoY), -$285.4M in net income, and -$323.2M in free cash flow against $529.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SNDX trading relative to its 50-day, 200-day, and 52-week technical levels?

SNDX last traded at $14.15 (-1.19% on volume of 4,882,226 shares), positioning the stock -17.64% below its 50-day simple moving average ($17.18) and -30.05% below its 200-day simple moving average ($20.23). Across its 52-week range of $12.80 to $25.59, SNDX sits at the 10.6% percentile with a 14-day RSI of 35.8 (NEUTRAL RANGE) and an implied next-earnings move of ±10.4% ($12.68 to $15.62).

SNDX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SNDX's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for SNDX.

Direct Sub-Reports: SNDX RQD Cockpit SNDX 12M Forecast SNDX Earnings & Move SNDX Dividends & DRIP SNDX Insiders & 13F SNDX Whale Options SNDX Profit Sankey SNDX News & Why